

DOI: 10.56871/RBR.2023.32.30.007

УДК 616.13.002.2-004.6+617.58+616.137.8-004.6+616-036.22

## ЗАБОЛЕВАНИЕ ПЕРИФЕРИЧЕСКИХ АРТЕРИЙ НИЖНИХ КОНЕЧНОСТЕЙ: СОВРЕМЕННАЯ ЭПИДЕМИОЛОГИЯ, РУКОВОДСТВО И ПЕРСПЕКТИВНЫЕ НАПРАВЛЕНИЯ (НАУЧНОЕ СОЧИНЕНИЕ)

© Аршед Ахмад Кучай<sup>1, 3, 4</sup>, Александр Николаевич Липин<sup>2, 3</sup>, Никита Николаевич Груздев<sup>2</sup>,  
Алексей Геннадьевич Борисов<sup>2</sup>, Валерия Андреевна Ширан<sup>4</sup>, Милена Курач<sup>4</sup>

<sup>1</sup> Клиника Мед2. 191036, г. Санкт-Петербург, ул. Восстания, 11

<sup>2</sup> Военно-медицинская академия им. С.М. Кирова. 194044, Российская Федерация, г. Санкт-Петербург, ул. Академика Лебедева, 6

<sup>3</sup> Городская больница № 14. 198099, Российская Федерация, г. Санкт-Петербург, ул. Косинова, 19/9

<sup>4</sup> Санкт-Петербургский государственный педиатрический медицинский университет. 194100, Российская Федерация, г. Санкт-Петербург, ул. Литовская, 2

**Контактная информация:** Аршед Ахмад Кучай — старший преподаватель кафедры анатомии человека; врач сердечно-сосудистый хирург, клинический исследователь Городского центра спасения конечностей. E-mail: drarshedcvs@gmail.com  
ORCID ID: 0000-0002-7974-9369 SPIN: 5455-9033

**Для цитирования:** Кучай А.А., Липин А.Н., Груздев Н.Н., Борисов А.Г., Ширан В.А., Курач М.. Заболевание периферических артерий нижних конечностей: современная эпидемиология, руководство и перспективные направления (научное сочинение) // Российские биомедицинские исследования. 2023. Т. 8. № 4. С. 54–64. DOI: <https://doi.org/10.56871/RBR.2023.32.30.007>

Поступила: 16.10.2023

Одобрена: 22.11.2023

Принята к печати: 20.12.2023

**Резюме.** Заболевание периферических артерий нижних конечностей (ЗПА) поражает более 230 миллионов взрослых пациентов во всем мире ежегодно. Это число указывает на высокую распространенность данного заболевания и связанных с ним негативных клинических исходов, например, ишемической болезни сердца, инсульта и ампутации. Исторически ЗПА недооценивалось медицинскими работниками и пациентами по нескольким причинам. Одна из них — ограниченная доступность в клиниках диагностического теста первой линии для ЗПА, такого как лодыжечно-плечевой индекс. Этот тест позволяет определить наличие стеноза и окклюзии артерий нижних конечностей. Еще одна причина — неправильное представление о том, что заболевания сосудов ног не являются фатальными. Однако за последние годы было проведено несколько исследований, которые показали недостаточное использование научно обоснованной терапии у пациентов с ЗПА. Это указывает на то, что нам необходимо обновить свои знания о ЗПА и улучшить практику лечения. Данное исследование представляет собой информацию о современной эпидемиологии ЗПА, включая распространенность заболевания, временные тенденции, факторы риска и осложнения. Оно также освещает современные методы диагностики, такие как физиологические тесты и методы визуализации, и основные пробелы в лечении ЗПА, включая медикаментозную терапию, лечебную физкультуру и реваскуляризацию. Этот научный материал поможет специалистам здравоохранения быть в курсе последних достижений в области ЗПА и обеспечить пациентам оптимальное лечение. В целом болезнь периферических артерий нижних конечностей является серьезной и распространенной проблемой, которая требует внимания и последовательного подхода к диагностике и лечению. Научные исследования играют важную роль в обеспечении оптимальной заботы о пациентах с ЗПА и снижении их риска осложнений.

**Ключевые слова:** атеросклероз; артерия; нижняя конечность; эпидемиология; сосуд.

## LOWER EXTREMITY PERIPHERAL ARTERY DISEASE: CONTEMPORARY EPIDEMIOLOGY, MANAGEMENT AND FUTURE TRENDS (A SCIENTIFIC STATEMENT)

© Arshed A. Kuchay<sup>1, 3, 4</sup>, Alexander N. Lipin<sup>2, 3</sup>, Nikita N. Gruzdev<sup>3</sup>, Aleksey G. Borisov<sup>3</sup>,  
Valeria A. Shiran<sup>4</sup>, Milena Kurach<sup>4</sup>



<sup>1</sup> Med2 clinic. Vosstaniya st., 11, Saint Petersburg, Russian Federation, 191036<sup>2</sup> Military Medical Academy named after S.M. Kirov. Akademichan Lebedev st., 6, Saint Petersburg, Russian Federation, 194044<sup>3</sup> City Hospital № 14. Kosinov str., 19/9, Saint Petersburg, Russian Federation, 198099<sup>4</sup> Saint Petersburg State Pediatric Medical University. Lithuania 2, Saint Petersburg, Russian Federation, 194100

**Contact information:** Arshed Ahmad Kuchay — Senior Lecturer of the Department of Human Anatomy; cardiovascular surgeon, clinical researcher of the City Limb Salvage Center. E-mail: drarshedcvs@gmail.com ORCID ID: 0000-0002-7974-9369 SPIN: 5455-9033

**For citation:** Kuchay AA, Lipin AN, Gruzdev NN, Borisov AG, Shiran VA, Kurach M. Lower extremity peripheral artery disease: contemporary epidemiology, management and future trends (a scientific statement) // Russian biomedical research (St. Petersburg). 2023;8(4):54-64. DOI: <https://doi.org/10.56871/RBR.2023.32.30.007>

Received: 16.10.2023

Revised: 22.11.2023

Accepted: 20.12.2023

**Abstract.** Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and limb outcomes such as amputation). Despite its prevalence and clinical importance, PAD has been historically underappreciated by health care professionals and patients. This underappreciation seems multifactorial (eg, limited availability of the first-line diagnostic test, the ankle-brachial index, in clinics; incorrect perceptions that a leg vascular disease is not fatal and that the diagnosis of PAD would not necessarily change clinical practice). In the past several years, a body of evidence has indicated that these perceptions are incorrect. Several studies have consistently demonstrated that many patients with PAD are not receiving evidence-based therapies. Thus, this scientific statement provides an update for health care professionals regarding contemporary epidemiology (eg, prevalence, temporal trends, risk factors, and complications) of PAD, the present status of diagnosis (physiological tests and imaging modalities), and the major gaps in the management of PAD (eg, medications, exercise therapy, and revascularization). The statement also lists key gaps in research, clinical practice, and implementation related to PAD. Mastermind efforts among different parties (eg, health care providers, researchers, expert organizations, and health care organizations) will be needed to increase the awareness and understanding of PAD and improve the diagnostic approaches, management, and prognosis of PAD.

**Key words:** atherosclerosis; artery; lower extremity; epidemiology; vessel.

## DEFINITION OF PAD

Historically, the terms peripheral artery (or arterial) disease and peripheral vascular disease have been used loosely. These terminologies have often included any or all atherosclerotic disease separate from cardiac disease, including carotid artery, renal artery, leg artery, and aortic diseases. Peripheral vascular disease may additionally include peripheral venous and lymphatic disease. In an era of precision medicine, we believe that precise definitions should be used. For the purpose of this scientific statement, we define peripheral artery disease (PAD) as “lower extremity PAD”. Specifically, we are referring to atherosclerotic obstruction from the aortoiliac segments to the pedal arteries.

## PREVALENCE AND TEMPORAL TRENDS

### Overall PAD

PAD is the third leading cause of atherosclerotic morbidity, following coronary heart disease and stroke. A systematic review of 34 studies (22 from high-income countries and 12 from low- and middle-income countries) demonstrated that the prevalence of PAD was ≈5% at 40 to 44 years of age and ≈12% at 70 to 74 years of age in both men and women in high-income coun-

tries. The prevalence of PAD in women in low- and middle-income countries was very similar to that in high-income countries, but the corresponding estimates for men in low- and middle-income countries compared with high-income countries were ≈2% and ≈8%, respectively. Between the years 2000 and 2010, the number of persons living with PAD increased by 13.1% in high-income countries and 28.7% in low- and middle-income countries.

Another recent systematic review estimated that 238 million people were living with PAD in 2015: 64 million living in high-income countries and 172 million living in low- and middle-income countries. Thus, PAD should be recognized as an increasingly global problem. A recent publication from the Global Burden of Disease study also indicates that PAD cases have risen each year since 1990. Similarly, disability-adjusted life-years, years of life lost, and years lived with disability increased over this period. These changes represent population growth rather than a change in age-specific incidence. Worldwide, the age-specific prevalence has been largely steady.

### Critical limb ischemia/amputation

Critical limb ischemia (CLI) (or chronic limb-threatening ischemia) is a severe form of PAD and usually defined as PAD with rest pain, nonhealing wounds, or tissue loss [1, 18]. A systematic

review has reported that the 1-year cumulative incidence for each of mortality and amputation is  $\approx 20\%$  among patients with CLI [18]. Because few population-based studies have investigated CLI, the epidemiology of CLI is not well understood. Using data from the Market scan database, which includes medical records from large employers' health plans, Medicare, and Medicaid, Nehler et al reported that the prevalence of CLI is 1.3%, accounting for 11% of diagnosed PAD cases, among the eligible study population  $\geq 40$  years of age. The rate of CLI admission was constant between 2003 and 2011, with  $\approx 150$  per 100 000 population [5].

The rate of lower extremity amputation declined from 2000 to 2009, but since has started to increase in people with diabetes. Specifically, the total annual amputation rate per 1000 individuals with diabetes was 3 in 2009 but exceeded 4.5 in 2015. Although the exact reasons behind this increase in lower extremity amputation in diabetes are unclear, it is important to note that the increase was consistently observed in both major (above ankle) and minor (below ankle) amputations. In the same period, the annual amputation rate in people without diabetes was constant at  $\approx 0.17$  per 1000 individuals.

### Lifetime risk

Lifetime risk estimate is a useful parameter to communicate long-term risk, especially among younger adults whose 10-year risk estimate is low and thus cannot inform long-term decision-making of preventive therapies. The American Heart Association (AHA) and the American College of Cardiology (ACC) 2018 Guideline on the Management of Blood Cholesterol provides a lifetime risk algorithm for people 20 to 59 years of age but does not take into account PAD. In this regard, a recent US study estimated lifetime risk of PAD by pooling 6 community-based US cohorts. According to that study, the lifetime risk of PAD was estimated to be  $\approx 30\%$  in Black men and women and  $\approx 20\%$  in White and Hispanic women and men. The study demonstrated that, for a given age, sex, and race/ethnicity, the lifetime risk estimate of PAD can vary by 3- to 5-fold depending on the status of the traditional risk factors for PAD such as smoking and diabetes.

## DIAGNOSIS

### Physiological testing

ABI, the ratio of ankle-to-brachial systolic blood pressure, is the first-line noninvasive diagnostic method for PAD, requiring standardized measurement methodology [6]. An ABI  $\leq 0.90$  is considered PAD. The diagnostic performance of ABI to detect PAD, with  $>50\%$  stenosis based on imaging modalities as the gold standard, is reasonably good, with sensitivity and specificity, respectively, at 61 to 73% and 83 to 96%.

Several studies have shown that women tend to have lower ABIs than men, potentially because of shorter height [8, 9]. A population-based study specifically explored this issue and found that, after accounting for demographic and clinical factors (eg, age and height), healthy women had on average an

ABI 0.017 lower than healthy men. Nonetheless, given the small difference from a clinical perspective for individual diagnosis, major clinical guidelines use the same ABI threshold of 0.90 in both sexes [1, 2, 20].

The ABI can be falsely high in the presence of stiffened ankle arteries related to medial artery calcification, a condition mostly observed in patients with diabetes or chronic kidney disease (CKD). In this scenario, it is recommended to measure the toe-brachial index (TBI), the ratio of the toe-to-brachial systolic blood pressure [1], because medial calcification rarely affects digital arteries (detailed techniques to measure TBI can be found elsewhere). In general, a TBI  $\leq 0.70$  is accepted as diagnostic for PAD [1, 2].

An ABI 0.90 to 1.0 is considered as borderline low ABI and cannot rule out PAD [8]. As detailed later in the statement, a body of evidence indicates that borderline low ABI is associated with increased risk of mortality and reduced physical function. In the case of borderline low ABI, particularly if symptoms suspect for exertional leg ischemia are present, the sensitivity to detect PAD can be improved by measuring ABI after a treadmill test (heel raise is an alternative method) [3, 4, 9, 20]. Although the criteria to evaluate postexercise ABI have not been standardized, postexercise ABI  $< 0.90$  or a drop of ABI  $> 20\%$  or ankle pressure drop  $> 30$  mm Hg are usually considered as diagnostic [10]. Postexercise ABI should be also considered in patients with potential intermittent claudication with normal ABI.

Another option to overcome ABI limitations is to study the ankle arteries' Doppler flow pattern and velocities. In my personal investigation of patients, the addition of tibial artery Doppler assessment identified 20% additional diseased legs missed by the ABI. Waveform analysis enables us to detect occlusive disease despite calcified arteries in patients with diabetes, and to identify those at high risk of cardiovascular disease (CVD) and limb events [3, 4].

### Imaging

Noninvasive imaging for the assessment of anatomy and severity of arterial stenosis for patients with PAD has evolved over the past decade because of technical improvements [11]. These include the ability to image distal vessels with calcification, lower contrast dose, and higher spatial resolution. The selection of imaging modalities to diagnose PAD should depend on several factors, including the patients' symptoms (eg, claudication versus CLI), kidney function, and ABIs.

## COMPUTED TOMOGRAPHIC ANGIOGRAPHY

Multidetector computed tomography scanners, including helical and multistation axial acquisitions, have now enabled the rapid scanning of the entire arterial system [12]. For evaluating the indication of revascularization in patients with PAD, both computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are accepted as appropriate imaging tests. The sensitivity and specificity of multidetector CTA compared with angiography is  $\approx 90\%$  for detecting PAD [13]. CTA uses iodinated



contrast and ionizing radiation to visualize pathology from the aorta to the lower extremity. The scan times take a few seconds, but diagnosis can be difficult in small tibial vessels with calcification and multiple occlusions. The recent development of 256-row CTA has made detecting stenosis in the tibial location possible [13], except in patients with calcified disease. New imaging techniques are being developed, including computed tomography perfusion to allow visualization of hypoxic regions of the lower extremity [14, 15], which can also demonstrate the effect of interventional treatment [7, 26, 31].

### MAGNETIC RESONANCE ANGIOGRAPHY

The sensitivity and specificity of MRA in detecting PAD with stenosis >50% is the same as CTA, 90 to 100% [35]. MRA has several advantages in diagnosing PAD over CTA. MRA requires no radiation, calcium does not interfere with the diagnosis, and it can be helpful in evaluating for bone marrow edema in patients who have ulcers with possible osteomyelitis. However, the procedure time is considerably longer. Also, there is a concern of gadolinium-induced nephrogenic systemic fibrosis in patients with decreased kidney function. Also, noncontrast MRA can be an option in some patients in capable facilities [16]. Another advantage of MRA is that it allows for hemodynamic measurements. Advanced techniques such as blood oxygenation level-dependent imaging and arterial spin labeling allow for assessing changes in perfusion to the calf muscle without gadolinium.

### DUPLEX ULTRASOUND

This modality is safe to all patients but is operator dependent. The sensitivity and specificity depend on several factors, including the presence of calcium in the arterial wall, the location or depth of the vessel, and the presence of multiple occlusions at different locations [16, 17]. The femoral and popliteal arteries can usually be assessed well, whereas the iliac vessels and aorta can be challenging because of the presence of bowel gas and body habitus. This modality can also take some time to perform a complete examination [6]. Ultrasound is often used to assess the effectiveness and patency after endovascular and surgical treatment. New advances using contrast-mediated ultrasound are being developed to evaluate perfusion to the lower extremity [17].

### Catheter-based angiography

Catheter-based angiography remains the gold standard for diagnosing PAD but is now limited to patients receiving endovascular revascularization [1]. New techniques are available that help to reduce the use of iodinated contrast, where CTA and MRA imaging can be fused to the angiogram, which has the potential to reduce the use of contrast and radiation [19]. Also, in some institutions, CO<sub>2</sub> angiography is used as a replacement or supplement (to reduce contrast) of conventional contrast-based angiography.

## RISK FACTORS

### Conventional risk factors

Evidence has supported traditional cardiovascular risk factors in PAD such as diabetes, smoking, dyslipidemia, and hypertension. A sedentary lifestyle also increases the risk in the development of PAD. The Edinburgh study reported that the risk of PAD is inversely related to physical activity. Of these conventional risk factors, diabetes and smoking are particularly strongly related to the development of PAD.

Individuals with diabetes are at an increased risk of developing asymptomatic or symptomatic PAD, with an increase in claudication of 2- to 3-fold greater compared with individuals without diabetes. Diabetes worsens outcomes in patients with PAD, by mostly affecting infrapopliteal arteries, increasing risk of CLI, amputation, and mortality [27]. Accordingly, ≈70% of nontraumatic lower extremity amputations occur in patients with diabetes, disproportionately to its overall prevalence of 12% [28, 30].

From another perspective, PAD is an important contributor to diabetes-related foot ulcer, a devastating condition with a high mortality risk and high medical cost affecting ≈13% of patients with diabetes in the United States [25, 27]. Up to half of patients with diabetes-related foot ulcer have PAD [28, 29]. The presence of PAD significantly worsens the prognosis in patients with diabetes-related foot ulcer with decreased healing rates, recurrence of ulceration, major limb amputation, and long-term survival.

Like diabetes, cigarette smoking doubles the risk of PAD compared with nonsmoking. The risk increases cumulatively with the number of cigarettes smoked and the start age of tobacco use, with starting before 16 years of age having the greatest risk [32, 33]. Although smoking cessation decreases the risk of PAD, a recent community-based cohort study demonstrated that it takes up to 30 years for the risk for PAD of the individuals who stopped smoking to reach that of individuals who do not smoke, whereas the risk for coronary heart disease returns to the baseline within 20 years (Figure 1).

Several studies have demonstrated total cholesterol and low levels of high-density lipoprotein cholesterol to be associated with PAD. In addition, apolipoprotein B and lipoprotein(a) levels have been shown as independent risk factors. A recent trial in patients with established CVD treated with hepatocyte-directed antisense oligonucleotide revealed a dose-dependent reduction of lipoprotein(a) [34], although the risk reduction of CVD including PAD is yet to be determined. A recent study has shown that triglyceride-rich lipoproteins may be especially important in the development of PAD. This observation has a clinical implication because icosapent ethyl, a triglyceride-lowering medication, has reduced major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) [37], although this trial has not reported results for PAD as an outcome.

### Nonconventional risk factors

PAD develops as an inflammatory cascade within arterial walls leading to atherosclerosis. In the Edinburgh Artery Study,




Fig. 1. Adjusted hazard ratio of 3 major atherosclerotic diseases according to time since quitting smoking: A — peripheral artery disease (PAD); B — coronary heart disease (CHD); C — stroke

Рис. 1. Скорректированный коэффициент опасности трех основных атеросклеротических заболеваний с момента прекращения курения: А — болезнь периферических артерий (PAD); В — ишемическая болезнь сердца (CHD); С — инсульт

inflammatory markers such as CRP (C-reactive protein) and IL-6 (interleukin-6) were found to be elevated in patients with symptomatic PAD. Studies have found that elevated levels of these inflammatory markers are associated with the most severe form of PAD and at the highest risk for CVD events. Hemostatic factors such as fibrinogen have been associated as an independent risk factor [36] and a strong predictor for the development of PAD.

Some studies suggest HIV as a risk factor for PAD. A US study including veterans showed that individuals with a sustained CD4 cell count  $<200$  cells/mm<sup>3</sup> had nearly 2-fold higher risk of PAD than individuals without HIV. There was no excess risk among individuals with a CD4 cell count  $\geq 500$  cells/mm<sup>3</sup>.

There is an evidence demonstrating an association between metals and cardiovascular disease [38]. Despite mounting evidence, the relationship is underappreciated. For instance, lead exposure has been shown to contribute to 10 times the number of cardiovascular deaths originally estimated. The association of blood lead and PAD in National Health and Nutrition Examination Survey 1999 to 2000, revealed that blood lead levels were 14% higher in cases with PAD than without. The Strong Heart Study evaluated the association of urine cadmium concentrations with the incidence of PAD, showing a prospective association between PAD and urine cadmium, independent from smoking. Higher urine cadmium levels have been associated with an increase in PAD severity, with no PAD having the lowest urine cadmium concentration and CLI with the highest levels of urine cadmium [39].

Air pollution exposure is linked with CVD, including PAD [39]. A population-based study of 18 000 individuals, associated urban living with a 2- to 3-fold increased risk of PAD compared with individuals living in rural areas. Similarly, those living near major roadways demonstrated a decrease in ABI [39].

Depression has emerged as a risk factor for the incidence and progression of PAD. This may be attributable to medication noncompliance or a decrease in physical activity. The Heart and Soul study revealed a hazard ratio of 2.09 (95% CI, 1.09–4.00) of developing PAD in patients with depressive symptoms after adjustment for sex and age [39]. Individuals with depression and PAD had worse functional outcomes, greater need for revascularization, and worse quality of life [40].

#### Microvascular abnormalities

PAD is usually recognized as a manifestation of macrovascular disease. However, several recent studies have indicated the potential involvement of microvascular disease in the progression of PAD. For example, an international consortium of individual-level data including 0.8 million adults has shown that albuminuria, a representative measure of microvascular disease, is more strongly associated with leg amputation than overall PAD (eg, adjusted hazard ratio  $\approx 6$  versus  $\approx 3$  in urinary albumin-to-creatinine ratio  $>300$  versus  $<10$  mg/g) [40, 42]. Moreover, a community-based cohort has demonstrated that the presence of any retinopathy (eg, hemorrhage or exudates) was more strongly associated with the incidence of CLI and PAD than that of coronary heart disease or stroke.

These observations have important diagnostic and therapeutic implications. For example, the ABI, which reflects stenosis in relatively large arteries, may not be helpful to classify the risk of CLI or leg amputation in some patients. A small case series has reported wide distribution of ABI (ranging from 0.7 to 1.1) in patients with diabetes and CLI. Of note, this study has demonstrated

that all patients had TBI <0.7. Also, the current therapeutic options for patients with PAD (eg, statins and antiplatelets) are mainly based on evidence to prevent large artery disease or macrovascular disease (ie, coronary heart disease and stroke). Thus, future investigations on any therapeutic options targeting microvascular disease would be warranted.

## COMPLICATIONS/COMORBIDITIES

### Leg Symptoms, Physical Function, and Quality of Life

The magnitude and significance of functional impairment in PAD is underappreciated. Despite difficulty walking long distances, individuals with PAD frequently have atypical leg symptoms that can be mistaken for comorbidities such as hip or knee arthritis or spinal stenosis. Some clinicians may attribute difficulty walking to normal aging. Some people with PAD report no exertional leg symptoms (ie, are asymptomatic) either because they have restricted their physical activity or slowed their walking speed to avoid ischemic leg symptoms. Therefore, it is important for clinicians to suspect the possibility of PAD in people who report difficulty in walking because of discomfort, weakness, cramping, or other symptoms in the hips, lower extremities, or feet. This is particularly the case if the symptoms resolve with rest and do not begin with rest and if the patient is >55 years of age with cardiovascular risk factors or a history of other cardiovascular disease. Cilostazol is the sole medication that the AHA/ACC PAD guideline recommends for ameliorating leg symptoms and improving walking distance in patients with PAD [1].

The gradual but progressive nature of functional decline in PAD is also difficult for clinicians to detect without objective testing. Furthermore, patients with PAD who restrict their activity to avoid leg symptoms may not appreciate that their walking endurance has declined and may report stabilization of leg symptoms even as their 6-minute walk distance has declined [35, 41]. A 6-minute walk test can be used to measure objective change in walking ability. Greater declines in 6-minute walk distance over time are associated with adverse outcomes, including mortality and mobility loss.

Atherosclerotic obstructions in lower extremity arteries prevent delivery of oxygenated blood to lower extremity skeletal muscle during walking activity, and many people with PAD cannot walk >2 to 3 blocks without stopping to rest because of ischemic leg symptoms such as cramping, weakness, or pain. It is important for health care providers to acknowledge patterns of atypical symptoms in patients with PAD [18, 21]. For example, hip, buttock, and lower back pain that occur with walking and resolve with rest are common in people with PAD and are likely attributable to atherosclerotic disease in locations proximal to the femoral arteries.

Consistent with the phenomenon of walking-induced ischemia, people with PAD have lower physical activity levels, poorer walking endurance, slower walking velocity, and poorer balance than people without PAD. More severe PAD is associated with lower physical activity levels and greater functional impairment. In the Walking and Leg Circulation Study cohort of 460 partici-

pants with PAD and 240 without PAD, lower ABI was progressively associated with a higher odds ratio of stopping to rest during a 6-minute walk test (eg, 11.7 [95% CI, 4.9–27.7] in ABI <0.50 and 6.6 [95% CI, 3.1–14.1] in ABI 0.50 to <0.70 compared with participants with ABI 0.9–1.5).

People with asymptomatic PAD also have significantly poorer functional performance than those without PAD. In 2 large observational studies of older community-dwelling men and women, ≈65% of those with an ABI <0.90 consistent with PAD were asymptomatic (ie, reported no exertional leg symptoms). Yet these individuals with asymptomatic PAD still had significantly slower walking velocity, lower physical activity, and poorer walking endurance than people without PAD who also report no exertional leg symptoms. Of note, borderline low ABI 0.9 to 1.0 has also been independently associated with reduced physical function.

In addition to poorer performance on objective assessments of functional performance, people with PAD report poorer quality of life than those without PAD. In the ARIC Study with 5115 older adults, lower ABI was independently associated with lower quality of life. The association was more evident for physical domains than mental domains of quality of life. This pattern was consistently observed in other studies. Nonetheless, in a study of 957 patients with PAD presenting to 16 specialty clinics in the United States, Netherlands, and Australia, 336 (35%) had significant mental health concerns consisting of depressive symptoms, anxiety, and stress.

Despite the significant functional impairment and impaired quality of life, people with PAD have traditionally been considered to have a benign natural history with regard to lower extremity outcomes [23]. This is because relatively few people with PAD will develop CLI or require amputation [31, 41]. The gradual decline in walking performance may be less perceptible to patients and to clinicians than acute events such as ALI, creating a false perception of a benign natural history of lower extremity PAD.

### Leg outcomes (CLI/ALI, leg amputations)

Lower extremity major amputations (typically defined at the level of the ankle or above) and ALI are often considered major adverse limb events. Amputation is not simply a complication but an important treatment option to save lives and proximal limbs. The association of PAD with mortality and other cardiovascular outcomes like myocardial infarction and stroke has been extensively evaluated. However, few studies have quantified the association of PAD (versus no PAD) with severe leg outcomes, although several clinical studies are exploring those outcomes only among PAD patients [35]. There are no validated models to identify patients with PAD who are likely to develop CLI or need amputation. To the best of our knowledge, whether ABI is associated with future CLI or leg amputation in the general population has yet to be reported.

ALI is a vascular emergency requiring immediate treatment for limb salvage and has recently attracted attention as an important complication of PAD. ALI usually represents a rapid or sudden (eg, <2 weeks) decrease of leg perfusion causing pain, pulseless,

pallor, sensory loss, or paralysis. However, to efficiently establish evidence on ALI, the field needs to develop a standardized definition of ALI [41].

### Mortality and cardiovascular outcomes

The ABI Collaboration reported a robust association of a low ( $\leq 0.90$ ) and high ( $>1.40$ ) ABI with all-cause and cardiovascular mortality from a meta-analysis of 16 population-based cohort studies. In persons with an ABI between 0.81 and 0.90, total mortality was doubled and in those with an ABI  $\leq 0.70$  it was quadrupled. In this study, borderline low ABI also demonstrated significantly elevated mortality. Multiple studies in diverse populations have demonstrated that persons with PAD have higher risk of other CVDs such as coronary heart disease, stroke, and abdominal aortic aneurysm [1, 39]. Another study adds heart failure to these outcomes. The elevated CVD risk has been shown to be only partially attributable to shared CVD risk factors, such that at any given level of CVD risk factors, PAD is independently related to future CVD events and mortality. PAD has also been shown to be predictive of future CVD events even when adjusted for other markers of subclinical atherosclerosis [40].


PAD recently gained attention in the context of polyvascular disease. This refers to a subset of patients with atherosclerotic involvement of multiple vascular beds, including PAD. In several trials assessing new lipid-lowering or antithrombotic therapies in the field of cardiovascular prevention such as the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) and the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation

Strategies), patients with polyvascular disease demonstrated higher risk than those without, which was translated into higher absolute risk reduction with these new treatments. For example, in the FOURIER trial, as anticipated, PAD plus myocardial infarction/stroke had the highest risk of major adverse cardiovascular events (CVD mortality, myocardial infarction, and stroke), with 2.5-year risk of 14.9% (Figure 2). It is notable that PAD without myocardial infarction/stroke had a higher risk of major adverse cardiovascular events (10.3%) than myocardial infarction/stroke without PAD (7.6%).

### CHALLENGES IN PAD MANAGEMENT

#### Underutilization of evidence-based preventive therapy

The most recent PAD guideline was developed in 2016 [1] and lists antiplatelet therapy, statins, antihypertensive agents, glycemic control, and smoking cessation as the Class I (strong) and IIa (moderate) recommendations. Despite these evidence-based guideline recommendations, patients with PAD remain undertreated. In an analysis of persons with PAD (defined by ABI  $\leq 0.9$ ) from the National Health and Nutrition Examination Survey, the use of aspirin, statins, and renin-angiotensin system inhibitors was only 35.8, 30.5 and 24.9%, respectively. A more contemporary study of patients undergoing peripheral revascularization, a subgroup at heightened risk for cardiovascular and limb ischemic outcomes, reported use of aspirin, P2Y<sub>12</sub> inhibitor, and renin-angiotensin system inhibitors in 67.3, 57.7 and 47.6% of patients, respectively, at discharge. In the latter analysis, only 61.7% of patients were discharged on a statin. Provider efforts to help patients with smoking cessation were examined among 1272 patients with PAD cared for in vascular specialty clinics followed in the PORTRAIT Registry (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories). In this study, 37.3% (n=474) were smoking actively at baseline. Of these, only 16% were referred to smoking cessation counseling, and 11% were prescribed pharmacological treatment. At 12 months, 72% of all individuals who smoked at baseline continued to smoke. The illustrated underutilization of preventive therapies may reflect the lack of clarity regarding prevention goals in PAD, because many trials have included PAD as a minority subgroup of broader atherosclerotic CVDs such as coronary heart disease and stroke. Nonetheless, these data clearly highlight the need for efforts to improve the use of evidence-based therapies in patients with PAD.



**Fig. 2.** Cumulative incidence of major adverse cardiovascular events in the placebo group according to CVD status at baseline. CVD indicates cardiovascular disease; MI — myocardial infarction; PAD — peripheral artery disease

**Рис. 2.** Кумулятивная частота основных неблагоприятных сердечно-сосудистых событий в группе плацебо в соответствии с состоянием CVD на базовом уровне. CVD указывает на сердечно-сосудистые заболевания; MI — инфаркт миокарда; PAD — заболевания периферических артерий

#### Underutilization of supervised exercise therapy

Supervised exercise is first-line therapy to improve walking impairment in people with PAD. Supervised treadmill exercise is the most thoroughly studied exercise therapy for people with PAD. More than 30 randomized clinical trials of supervised treadmill exercise in people with PAD involving >1400 participants have been completed. In 1 meta-analysis, mean improvement in treadmill walking distance was 180 meters and mean improvement in pain-free walking distance was 128 meters, compared with a

nonexercise control group. Supervised exercise also significantly and meaningfully improves 6-minute walk distance and health-related quality of life in people with PAD. Several randomized trials have also demonstrated that arm and leg ergometry exercise, respectively, each significantly improve walking distance in people with PAD.

Structured home-based walking exercise interventions receive Class IIa recommendations in the AHA/ACC 2016 PAD guideline and have the potential to overcome some barriers of supervised exercise programs. However, home-based walking exercise interventions have had mixed benefits for improving walking ability in people with PAD [43, 44]. Three randomized trials of home-based walking exercise significantly improved walking ability, measured by 6-minute walk distance and treadmill walking performance, compared with a control group that did not exercise. These effective interventions have required periodic visits to the medical center for in-person coaching and feedback. A 6-month home-based exercise intervention that included weekly on-site visits to the medical center while helping patients with PAD adhere to walking exercise at home improved the 6-minute walk distance by 52 meters relative to a control group. In contrast, a 9-month randomized trial of home-based exercise that primarily relied on telephone calls, tapering to once per month did not show significant benefit compared with usual care. Although home-based exercise interventions can significantly and meaningfully improve 6-minute walk distance, it is important to keep in mind that the most effective interventions have incorporated regular visits to the medical center. A recent randomized clinical trial of home-based exercise in 305 participants with PAD demonstrated that exercise at an intensity that induced ischemic leg symptoms, but not exercise conducted at a comfortable pace without ischemic leg symptoms, significantly improved walking performance [44].

## CHALLENGES IN REVASCULARIZATION

### Revascularization for intermittent claudication

Guidelines from the AHA/ACC [1] and the Society for Vascular Surgery [22] recommend best medical treatment as the first-line treatment for claudication, with revascularization reserved for only refractory cases. These recommendations are based on data showing that there is a relatively low likelihood of limb loss associated with mild PAD and that long-term improvements in symptomatology may be limited. For example, recent data from the Invasive Revascularization or Not in Intermittent Claudication trial demonstrated that, after 5 years of follow-up, revascularization for claudication lost any early benefit and did not result in long-term health-related quality of life compared with best medical therapy. Despite guidelines recommending medical management as the first-line therapy for claudication, recent registry data from the Vascular Quality Initiative demonstrate that 27% of all open bypass procedures and even a higher percentage of endovascular interventions are performed for claudication. It is possible that many of the patients undergoing revascularization for claudication

experienced severe claudication symptoms and that conservative management failed. For instance, in the CLEVER study (Claudication: Exercise Versus Endoluminal Revascularization) [45], the revascularization group and the supervised exercise therapy group had better 18-month outcomes than optimal medical care alone. Quality improvement initiatives aimed at reducing unnecessary procedures are emerging to address outlier behavior in the overuse of invasive interventions for mild disease [47]. Higher-quality data about the benefits of revascularization for severe claudication symptoms are needed.

## PERCUTANEOUS REVASCULARIZATION

The impact of percutaneous intervention in CLI is a subject of emergent research and the focus of active investigation. In a large observational study, percutaneous intervention compared with surgical therapy was associated with reduced in-hospital mortality (2.34% versus 2.73%,  $P<0.001$ ), length of stay (8.7 days versus 10.7 days,  $P<0.001$ ), and cost of hospitalization (\$31 679 versus \$32 485,  $P<0.001$ ) despite similar rates of major amputation (6.5% versus 5.7%,  $P=0.75$ ) [5]. Also, the increase in percutaneous leg revascularization has been related to a decline in leg amputation in the United States [5]. Although many observational studies have suggested the benefit of percutaneous intervention in decreased amputation rates and mortality, to date, only one trial has compared percutaneous intervention with medical or surgical therapy in patients with CLI.

Furthermore, most studies to date have failed to account for anatomic factors that may influence patient selection toward percutaneous versus surgical intervention. The Society for Vascular Surgery has developed 2 limb-staging classification schemes to allow for more objective comparison of revascularization outcomes. The Wound, Ischemia, and foot Infection (WIFI) stage [48] and the Global Anatomic Staging System (GLASS) are 2 classification systems intended to permit more meaningful analysis of outcomes for various forms of therapy in heterogeneous populations with CLI and should be reported whenever possible in major comparative studies moving forward.

With the increased use of percutaneous intervention in PAD, restenosis has been a continual obstacle. A growing proportion of patients are undergoing lower extremity bypass for a prior failed percutaneous intervention, and these secondary revascularization procedures have been associated with inferior 1-year outcomes. Although many devices lack comparative proof to support their use as a definite approach, multiple randomized studies of drug-eluting stent or drug-coated balloon show promising results for decreasing restenosis rates in the femoral-popliteal segment. Among the current therapeutic options, the paclitaxel-eluting or paclitaxel-coated devices consistently show a significantly higher primary patency rate, better target lesion revascularization rate, and cost effectiveness. Although a meta-analysis has reported an increase of mortality in patients receiving paclitaxel drug-coated balloon/drug-eluting stent DES compared with controls, there is some recent

evidence against this finding. Nonetheless, the continued use of these devices should be individualized, carefully balancing the risks and benefits.

## SURGICAL REVASCULARIZATION

The majority of open surgery for lower extremity revascularization is performed for CLI [18, 21, 26]. Although lower extremity revascularization for PAD is becoming increasingly common in the Russian Federation and all around the world, the rate of open surgery is stable or declining [31, 35, 41]. Approximately 40% of all lower extremity revascularization procedures performed in the Russian federation are open bypass surgery (versus 60% endovascular) because of the lower morbidity associated with endovascular procedures [46,48].

However, there is still substantial debate about the efficacy of open surgery versus endovascular interventions for the treatment of PAD. In the BASIL trial (Bypass versus Angioplasty in Severe Ischemia of the Leg), which is the only randomized controlled trial on the topic to date, a bypass-first strategy had overall outcomes similar to an angioplasty-first strategy [24]. However, there was a significant overall survival benefit and a trend toward a benefit for amputation-free survival associated with open surgery among patients who survived >2 years. Since that trial concluded >15 years ago, there have been major advances in endovascular technology that are associated with better long-term outcomes at higher costs. As a result, the efficacy of endovascular versus open surgery revascularization for PAD remains unknown. The BEST-CLI trial (Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia), which just completed enrollment, will hopefully clarify optimal therapies for CLI [31]. As noted earlier, the application of objective anatomic staging systems such as Wifl or GLASS are necessary to equalize clinical and anatomic factors in addition to baseline patient risk factors in clinical trials and observational studies moving forward.

Lower extremity PAD is a global public health issue that has been systematically understudied and underappreciated. This statement summarizes major gaps in research, clinical practice, and implementation related to PAD. Health care professionals, researchers, expert organizations, health care organizations, government agencies, industry, and the community should collaborate to increase the awareness and understanding of PAD and improve the quality of PAD diagnosis, management, prognosis and treatment.

## ДОПОЛНИТЕЛЬНАЯ ИНФОРМАЦИЯ

**Вклад авторов.** Все авторы внесли существенный вклад в разработку концепции, проведение исследования, прочли и одобрили финальную версию перед публикацией.

**Конфликт интересов.** Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией.

**Источник финансирования.** Авторы заявляют об отсутствии внешнего финансирования при проведении исследования.

## ADDITIONAL INFORMATION

**Author contribution.** Thereby, all authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work.

**Competing interests.** The authors declare that they have no competing interests.

**Funding source.** This study was not supported by any external sources of funding.

## ЛИТЕРАТУРА / REFERENCES

1. Gerhard-Herman M.D., Gornik H.L., Barrett C. et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017; 135: e726–79. DOI: 10.1161/CIR.0000000000000471.
2. Hirsch A.T., Criqui M.H., Treat-Jacobson D. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA*. 2001; 286: 1317–24. DOI: 10.1001/jama.286.11.1317.
3. McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. *Circ Res*. 2015; 116: 1540–50. DOI: 10.1161/CIRCRESAHA.114.303517.
4. Fowkes F.G., Rudan D., Rudan I. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet*. 2013; 382: 1329–40. DOI: 10.1016/S0140-6736(13)61249-0.
5. Agarwal S., Sud K., Shishehbor M.H. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: from 2003–2011. *J Am Coll Cardiol*. 2016; 67: 1901–13. DOI: 10.1016/j.jacc.2016.02.040.
6. Lijmer J.G., Hunink M.G., van den Dungen J.J. et al. ROC analysis of noninvasive tests for peripheral arterial disease. *Ultrasound Med Biol*. 1996; 22:391–398. DOI: 10.1016/0301-5629(96)00036-1.
7. Stivalet O., Paisant A., Belabbas D. et al. Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography. *PLoS One*. 2019; 14: e0219082. DOI: 10.1371/journal.pone.0219082.
8. Herraiz-Adillo Á., Cavero-Redondo I., Álvarez-Bueno C. et al. The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: a systematic review and meta-analysis. *Atherosclerosis*. 2020; 315: 81–92. DOI: 10.1016/j.atherosclerosis.2020.09.026.
9. Allison M.A., Cushman M., Solomon C. et al. Ethnicity and risk factors for change in the ankle-brachial index: the Multi-Ethnic Study of Atherosclerosis. *J Vasc Surg*. 2009; 50:1049–56. DOI: 10.1016/j.jvs.2009.05.061.



10. Aboyans V., Lacroix P., Tran M.H. et al. The prognosis of diabetic patients with high ankle-brachial index depends on the coexistence of occlusive peripheral artery disease. *J Vasc Surg.* 2011; 53: 984–91. DOI: 10.1016/j.jvs.2010.10.054.
11. Misra S., Shishehbor M.H., Takahashi E.A. et al. on behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing. Perfusion assessment in critical limb ischemia: principles for understanding and the development of evidence and evaluation of devices: a scientific statement from the American Heart Association. *Circulation.* 2019; 140: e657–72. DOI: 10.1161/CIR.0000000000000708.
12. Kumamaru K.K., Hoppel B.E., Mather R.T., Rybicki F.J. CT angiography: current technology and clinical use. *Radiol Clin North Am.* 2010; 48: 213–35, vii. DOI: 10.1016/j.rcl.2010.02.006.
13. Buls N., de Brucker Y., Aerden D. et al. Improving the diagnosis of peripheral arterial disease in below-the-knee arteries by adding time-resolved CT scan series to conventional run-off CT angiography. First experience with a 256-slice CT scanner. *Eur J Radiol.* 2019; 110: 136–41. DOI: 10.1016/j.ejrad.2018.11.030.
14. Hur S., Jae H.J., Jang Y. et al. Quantitative assessment of foot blood flow by using dynamic volume perfusion CT technique: a feasibility study. *Radiology.* 2016; 279: 195–206. DOI: 10.1148/radiol.2015150560.
15. Sah B.R., Veit-Haibach P., Strobel K. et al. CT-perfusion in peripheral arterial disease – correlation with angiographic and hemodynamic parameters. *PLoS One.* 2019; 14: e0223066. DOI: 10.1371/journal.pone.0223066.
16. Allard L., Cloutier G., Durand L.G. et al. Limitations of ultrasonic duplex scanning for diagnosing lower limb arterial stenoses in the presence of adjacent segment disease. *J Vasc Surg.* 1994; 19: 650–7. DOI: 10.1016/s0741-5214(94)70038-9.
17. Hou X.X., Chu G.H., Yu Y. Prospects of contrast-enhanced ultrasonography for the diagnosis of peripheral arterial disease: a meta-analysis. *J Ultrasound Med.* 2018; 37: 1081–90. DOI: 10.1002/jum.14451.
18. Kuchay A.A., Lipin A.N., Antropov A.V. et al. Treatment of multilevel lesions of arteries in lower extremities in cases of CLTI. *Medical Alliance.* 2022; 10(S3): 187–9. EDN IWSMIP.
19. Serhal A., Koktzoğlu I., Edelman R.R. Feasibility of image fusion for concurrent MRI evaluation of vessel lumen and vascular calcifications in peripheral arterial disease. *AJR Am J Roentgenol.* 2019; 212: 914–8. DOI: 10.2214/AJR.18.20000.
20. US Preventive Services Task Force: Curry S.J., Krist A.H., Owens D.K. et al. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: US Preventive Services Task Force recommendation statement. *JAMA.* 2018; 320: 177–83. DOI: 10.1001/jama.2018.8357.
21. Kuchay A.A., Lipin A.N., Karelina N.R., Artyukh L.Yu. Revascularization of lower limb based on the angiosome concept with early local flap reconstruction (A CASE REPORT). *Forcipe.* 2022; 5(4): 29–35.
22. Conte M.S., Pomposelli F.B. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. *J Vasc Surg.* 2015; 61(3 suppl): 1S. DOI: 10.1016/j.jvs.2014.12.006.
23. Lindholt J.S., Sogaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. *Lancet.* 2017; 390: 2256–65. DOI: 10.1016/S0140-6736(17)32250-X.
24. Ortmann J., Nüesch E., Traupe T. et al. Gender is an independent risk factor for distribution pattern and lesion morphology in chronic critical limb ischemia. *J Vasc Surg.* 2012; 55: 98–104. DOI: 10.1016/j.jvs.2011.07.074.
25. Pande R.L., Creager M.A. Socio economic inequality and peripheral artery disease prevalence in US adults. *Circ Cardiovasc Qual Outcomes.* 2014; 7: 532–9. DOI: 10.1161/CIRCOUTCOMES.113.000618.
26. Kuchay A.A., Lipin A.N., Karelina N.R. et al. Revascularization in extended occlusions of the superficial part of the femoral artery and multi-storey lesions of the arteries of the lower extremity. *Forcipe.* 2022; 5(3): 4–14.
27. Zhang P., Lu J., Jing Y. et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. *Ann Med.* 2017; 49: 106–16. DOI: 10.1080/07853890.2016.1231932.
28. Hinchliffe R.J., Forsythe R.O., Apelqvist J. et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev.* 2020; 36(suppl 1): e3276. DOI: 10.1002/dmrr.3276.
29. Morbach S., Furchert H., Gröblichhoff U. et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. *Diabetes Care.* 2012; 35: 2021–7. DOI: 10.2337/dc12-0200.
30. Bevilacqua N.J., Rogers L.C., Armstrong D.G. Diabetic foot surgery: classifying patients to predict complications. *Diabetes Metab Res Rev.* 2008; 24(suppl 1): S81–3. DOI: 10.1002/dmrr.858.
31. Kuchay A.A., Lipin A. N., Antropov A.V. et al. Hybrid approach in treatment of extended occlusive arteries of the lower extremities in CLTI. *Angiology and vascular surgery;* 2019; 25(S2): 260–4.
32. Willigendael E.M., Teijink J.A., Bartelink M.L. et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. *J Vasc Surg.* 2004; 40: 1158–65. DOI: 10.1016/j.jvs.2004.08.049.
33. Leng G.C., Lee A.J., Fowkes F.G. et al. The relationship between cigarette smoking and cardiovascular risk factors in peripheral arterial disease compared with ischaemic heart disease. The Edinburgh Artery Study. *Eur Heart J.* 1995; 16: 1542–8. DOI: 10.1093/oxfordjournals.eurheartj.a060775.
34. Tsimikas S., Karwatowska-Prokopczuk E., Gouni-Berthold I. et al. AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. *N Engl J Med.* 2020; 382: 244–55. DOI: 10.1056/NEJMoa1905239.
35. Kuchay A.A., Lipin A. N., Antropov A.V. et al. Treatment for multi-story lesions of lower extremities in CLTI. *Angiology and vascular surgery;* 2021; 27(S2): 410–2.
36. Aday A.W., Lawler P.R., Cook N.R. et al. Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence.

- Circulation. 2018; 138: 2330–41. DOI: 10.1161/CIRCULATIONAHA.118.035432.
37. Bhatt D.L., Steg P.G., Miller M. et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med.* 2019; 380: 11–22. DOI: 10.1056/NEJMoa1812792.
  38. Chowdhury R., Ramond A., O’Keeffe L.M. et al. Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ.* 2018; 362: k3310. DOI: 10.1136/bmj.k3310.
  39. Hoffmann B., Moebus S., Kröger K. et al. Residential exposure to urban air pollution, ankle-brachial index, and peripheral arterial disease. *Epidemiology.* 2009; 20: 280–8. DOI: 10.1097/EDE.0b013e-3181961ac2.
  40. Ruo B., Liu K., Tian L. et al. Persistent depressive symptoms and functional decline among patients with peripheral arterial disease. *Psychosom Med.* 2007; 69: 415–24. DOI: 10.1097/PSY.0b013e318063ef5c.
  41. Kuchay A.A., Lipin A. N., Antropov A.V. et al. Concept of a “DISTAL HYBRID” for long occlusions of the superficial femoral artery with severe damage to the outflow pathways at critical ischemia of the lower extremity. *Angiology and vascular surgery.* 2022; 28(S1): 157–61.
  42. Yang C., Kwak L., Ballew S.H. et al. Retinal microvascular findings and risk of incident peripheral artery disease: an analysis from the Atherosclerosis Risk in Communities (ARIC) Study. *Atherosclerosis.* 2020; 294: 62–71. DOI: 10.1016/j.atherosclerosis.2019.10.012.
  43. Collins T.C., Lunos S., Carlson T. et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. *Diabetes Care.* 2011; 34: 2174–9. DOI: 10.2337/dc10-2399.
  44. McDermott M.M., Spring B., Tian L. et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. *JAMA.* 2021; 325: 1266–76. DOI: 10.1001/jama.2021.2536.
  45. Giaccopo D., Cassese S., Harada Y. et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. *JACC Cardiovasc Interv.* 2016; 9: 1731–42. DOI: 10.1016/j.jcin.2016.06.008.
  46. Kuchay A.A., Lipin A. N., Antropov A.V. et al. Hybrid approach to long occlusion of SFA with CLTI. *Angiology and vascular surgery.* 2022; 28(S1): 161–3.
  47. Rosenfield K., Jaff M.R., White C.J. et al. LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. *N Engl J Med.* 2015; 373: 145–53. DOI: 10.1056/NEJMoa1406235.
  48. Kurianov P., Lipin A., Antropov A. et al. Popliteal artery angioplasty for chronic total occlusions with versus without the distal landing zone. *Annals of vascular surgery;* 2020; 62(68): 417–25.